An early arrival among '17 biotech IPOs, AnaptysBio keeps to its range in successful $75M play
AnaptysBio has upped its shares but still managed to hit the mid-point of its IPO range, raising $75 million.
The successful outing marks an encouraging start to the year for biotech IPOs, which have been in rough terrain after a year of ups and downs on Wall Street. Right now, a mid-range IPO looks pretty good. And it perhaps bodes well for the initial lineup of biotech companies looking to start the year with an IPO raise.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.